A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies

Afshin Forouzannia, Joan Schiller, Jordan Berlin, Paul Hutson, David Boothman, Barry Storer, George Wilding, Minesh Mehta

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Purpose: To determine the maximum-tolerated dose (MTD) of daily Topotecan with full-dose thoracic radiotherapy (XRT). Methods and materials: Patients with advanced thoracic malignancies requiring full dose radiation received daily I.V. Topotecan prior to each daily session of XRT to 60Gy over 6 weeks. Dose levels (and subjects studied at each) have been 0.2 (N=7), 0.3 (N=5), 0.4 (N=7), and 0.5mg/m2 per day (N=5) in a best-of-five design. Tumor response was assessed at 4-8 weeks after completion of therapy. Results: From March 1995 to December 1999, a total of 24 patients were treated. The MTD of Topotecan was 0.4mg/m2 per day, based on dose limiting toxicities (DLTs) observed at 0.5mg/m2 per day, which were grade 4 hematological toxicities or diarrhea and grade 3 esophagitis. Tumor responses included: zero complete response (CR), nine partial responses (PR), five stable disease (SD), nine progressive disease (PD) and one not evaluated (NE). Additionally, local response was also assessed separately (within the XRT ports) and there were 10 PR, 12 SD, 1 PD, and 1 NE. Conclusion: the MTD of Topotecan with concomitant thoracic radiotherapy is 0.4mg/m2 per day. The DLTs observed were grade 4 diarrhea, grade 3 esophagitis and grade 4 hematological toxicities. Based on the known radiosensitizing effect of Topotecan, this dose is recommended for phase II testing.

Original languageEnglish (US)
Pages (from-to)111-119
Number of pages9
JournalLung Cancer
Issue number1
StatePublished - Apr 2004


  • Lung cancer
  • Phase I
  • Radiosensitizers
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies'. Together they form a unique fingerprint.

Cite this